文献速递新发突发、热带与寄生虫病

萘酚喹-阿奇霉素复方制剂用于东南亚疟疾预防的3期双盲随机安慰剂对照试验

Efficacy and Safety of a Naphthoquine-Azithromycin Coformulation for Malaria Prophylaxis in Southeast Asia: A Phase 3, Double-blind, Randomized, Placebo-controlled Trial.
PubMed 文献 · Clin Infect Dis · 2021-01-01

在中缅边境村庄开展3期双盲随机安慰剂对照试验,631名5-65岁居民按月单次口服萘酚喹-阿奇霉素固定剂量复方(NQAZ)或安慰剂。意向性分析显示NQAZ保护效力93.62%(95%CI 91.72%-95.52%),对间日疟和卵形疟100%保护,耐受性良好。

要点

  • 每月单次NQAZ对疟原虫感染保护效力93.62%(95%CI 91.72%-95.52%)。
  • 对间日疟和卵形疟达100%保护,3例突破感染均为急性恶性疟。
  • 肝转氨酶一过性升高治疗组5.6% vs 安慰剂组2.2%(P>.05)。

核心结论

  • 每月单次NQAZ片剂预防疟原虫感染耐受性好且高效,可能有助于在G6PD缺乏高流行区消除间日疟。

研究设计与样本

  • 在中国-缅甸边境村庄开展随机、安慰剂对照、双盲3期试验。
  • 共631名5-65岁居民随机分为药物组(n=319)和安慰剂组(n=312),每月单次给药。
  • 每周随访监测不良事件和疟疾感染,531名受试者完成试验。

主要发现

  • 完成试验者中,安慰剂组46例、治疗组3例血涂片疟原虫阳性。
  • 意向性分析保护效力93.62%(95%CI 91.72%-95.52%),符合方案分析93.04%(95%CI 90.98%-95.1%)。
  • NQAZ组3例涂片阳性均为急性恶性疟,对间日疟和卵形疟提供100%保护。
  • 治疗组5.6%出现一过性肝转氨酶升高,安慰剂组2.2%(P>.05)。

临床怎么用

  • 每月单次NQAZ可作为疟疾预防方案,尤其适用于G6PD缺乏高流行区间日疟消除。
  • 用药期间需关注肝转氨酶一过性升高,但组间差异无统计学意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A prophylactic antimalarial drug that is both effective for protection and improves compliance is in high demand. METHODS: We conducted a randomized, placebo-controlled, double-blinded phase 3 trial to evaluate the 1:1 fixed-dose combination of naphthoquine-azithromycin (NQAZ) for safety and protection against Plasmodium infections in villages along the China-Myanmar border. A total of 631 residents, 5-65 years of age, were randomized into the drug group (n = 319) and the placebo group (n = 312) to receive NZAQ and placebo, respectively, as a single-dose monthly treatment. Follow-ups were conducted weekly to monitor for adverse events and malaria infections. RESULTS: Of the 531 subjects completing the trial, there were 46 and 3 blood smear-positive Plasmodium infections in the placebo and treatment groups, respectively. For the intent-to-treat analysis, the single-dose monthly NQAZ treatment had 93.62% protective efficacy (95% confidence interval [CI]: 91.72%-95.52%). For the per-protocol analysis, NQAZ treatment provided a 93.04% protective efficacy (95% CI: 90.98%-95.1%). Three smear-positive cases in the NQAZ group were all due to acute falciparum malaria. In comparison, NQAZ treatment provided 100% protection against the relapsing malaria Plasmodium vivax and Plasmodium ovale. The treatment group had 5.6% of participants experiencing transient elevation of liver aminotransferases compared with 2.2% in the placebo group (P > .05). CONCLUSIONS: Monthly prophylaxis with NQAZ tablets was well tolerated and highly effective for preventing Plasmodium infections. It may prove useful for eliminating P. vivax in areas with a high prevalence of glucose-6-phosphate dehydrogenase deficiency in the population. CLINICAL TRIALS REGISTRATION: ChiCTR1800020140.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Yang H, Wang J, Liu H, et al. Efficacy and Safety of a Naphthoquine-Azithromycin Coformulation for Malaria Prophylaxis in Southeast Asia: A Phase 3, Double-blind, Randomized, Placebo-controlled Trial. Clin Infect Dis. 2021. PMID: 32687174. doi:10.1093/cid/ciaa1018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。